Core Insights - SNAP Biosciences, a subsidiary of Coeptis Therapeutics, has entered into a licensing agreement with Monarch Therapeutics to develop and commercialize its Snap-Car NK cell therapy platform in oncology using Monarch's small molecule adaptor technology [1][4]. Group 1: Licensing Agreement - The agreement allows SNAP Biosciences to utilize Monarch's small-molecule adaptor technology, enhancing the functionality of the Snap-Car universal CAR-based receptor platform [2]. - Monarch's adaptor technology enables SNAP-CAR cells to be directed by small molecules, improving precision, flexibility, and modular potential across various therapeutic areas [2][3]. Group 2: Technology and Innovation - The integration of Monarch's small molecule adaptors allows Snap-Car NK cells to target multiple tumor antigens and modulate their activity in real-time, addressing tumor heterogeneity and antigen escape challenges [3]. - This collaboration aims to develop more potent, flexible, and scalable NK therapies for difficult-to-treat cancers [4]. Group 3: Financial Terms - Under the agreement, Monarch will receive an upfront licensing payment, future development milestone payments, and royalties on net sales [4]. Group 4: Company Background - Monarch Therapeutics is a pre-clinical stage biotechnology company focused on next-generation immunotherapies, particularly in solid tumors [5]. - SNAP Biosciences specializes in developing Snap-Car, a universal CAR cell therapy that allows programmable antigen targeting [6]. - Coeptis Therapeutics Holdings, Inc. focuses on innovative cell therapy platforms for cancer and other diseases, aiming to improve patient outcomes through advanced research and development [7].
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology